Abstract
Purpose of Review
To evaluate the impact of allergic rhinitis (AR) on the development of asthma and to update readers on recent literature suggesting that early treatment of allergic subjects with immunotherapy may prevent asthma onset.
Recent Findings
AR is frequently associated with asthma, leading to the concept that these two conditions are different aspects of the same disease. There is increasing evidence that AR precedes the onset of asthmatic symptoms and current treatment strategies are beneficial in symptom control with no impact prevention. There is limited knowledge about the risk factors responsible for the progression of AR to asthma, though recent data supports the notion that it is possible to prevent asthma onset by allergen immunotherapy.
Summary
Despite significant advances in specific immunotherapy (SIT) therapy strengthening its efficacy in AR and possible prevention of progression to asthma, the adoption of this therapeutic strategy is still restricted in comparison to therapies directed towards treatment of AR symptoms. Unlike corticosteroids and other symptomatic therapies, the benefit of SIT treatment in allergic individuals has been shown to prevent the development of allergic conditions. Hence, large well-conducted randomized clinical trials with long-term efficacy of SIT are required to confirm or refute the concept that SIT may abrogate the progression of AR to asthma in patients.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Bro JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. 2017.
Togias A. Mechanisms of nose-lung interaction. Allergy. 1999;54(s57):94–105.
Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol. 2001;1(1):7–13.
•• Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93–100. This paper gathers epidemiologic, pathophysiologic, and clinical evidence for an integrated view of rhinitis and asthma defining them unitarily as “united airway disease.
Jeffery CC, Bhutani M, Vliagoftis H, Wright ED, Seikaly H, Côté DWJ. Association between allergic rhinitis and asthma in a Northern Alberta cohort. J Otolaryngol Head Neck Surg. 2013;42(1):58.
Ciprandi G, Cirillo I. The lower airway pathology of rhinitis. J Allergy Clin Immunol. 2006;118(5):1105–9.
Lin J, Su N, Liu G, Yin K, Zhou X, Shen H, et al. The impact of concomitant allergic rhinitis on asthma control: a cross-sectional nationwide survey in China. J Asthma. 2014;51(1):34–43.
Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47.
Cibella F, Ferrante G, Cuttitta G, Bucchieri S, Melis MR, La Grutta S, et al. The burden of rhinitis and rhinoconjunctivitis in adolescents. Allergy Asthma Immunol Res. 2015;7(1):44–50.
Navarro AM, Delgado J, Muñoz-Cano RM, Dordal MT, Valero A, Quirce S, et al. Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report. Clin Transl Allergy. 2017;7:16.
Ciprandi G, Caimmi D, Miraglia Del Giudice M, La Rosa M, Salpietro C, Marseglia GL. Recent developments in United airways disease. Allergy Asthma Immunol Res. 2012;4(4):171–7.
Bonay M, Neukirch C, Grandsaigne M, Leçon-Malas V, Ravaud P, Dehoux M, et al. Changes in airway inflammation following nasal allergic challenge in patients with seasonal rhinitis. Allergy. 2006;61(1):111–8.
Zhu Z, Xie Y, Guan W, Gao Y, Xia S, Zhong N, et al. FeNO for detecting lower airway involvement in patients with allergic rhinitis. Exp Ther Med. 2016;12(4):2336–40.
Braunstahl G-J, Overbeek SE, Fokkens WJ, Kleinjan A, Mceuen AR, Walls AF, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med. 2001;164(5):858–65.
Ciprandi G, Signori A, Tosca MA, Cirillo I. Spirometric abnormalities in patients with allergic rhinitis: Indicator of an “asthma march”? Am J Rhinol Allergy. 2011;25(5):181–5.
Lambrecht BN, Hammad H. Asthma: the importance of dysregulated barrier immunity. Eur J Immunol. 2013;43(12):3125–37.
Pawankar R, Bunnag C, Khaltaev N, Bousquet J. Allergic rhinitis and its impact on asthma in Asia Pacific and the ARIA update 2008. World Allergy Organ J. 2012;5(Suppl 3):S212–7.
Linneberg A, Henrik Nielsen N, Frølund L, Madsen F, Dirksen A, Jørgensen T, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002;57(11):1048–52.
• Cirillo I, Ricciardolo FLM, Medusei G, Signori A, Ciprandi G. Exhaled nitric oxide may predict bronchial hyperreactivity in patients with allergic rhinitis. Int Arch Allergy Immunol. 2013;160(3):322–8. This study highlights the relevance of FeNO as a possible predictive marker for BHR in AR patients and underlines the close link between upper and lower airways.
Lee E, Lee SH, Kwon J-W, Kim Y, Cho H-J, Yang S-I, et al. A rhinitis phenotype associated with increased development of bronchial hyperresponsiveness and asthma in children. Ann Allergy Asthma Immunol. 2016;117(1):21–28.e1.
Nickel R, Lau S, Niggemann B, Gruber C, von Mutius E, Illi S, et al. Messages from the German multicentre allergy study. Pediatr Allergy Immunol. 2002;13(s15):7–10.
Spergel J, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6):S118–27.
Asher MI, Montefort S, Björkstén B, Lai CKW, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet (Lond Engl). 2006;368(9537):733–43.
Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D. Phase III study groupthe I. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110–24.
Yoo B, Park Y, Park K, Kim H. A 9-year trend in the prevalence of allergic disease based on national health insurance data. J Prev Med Public Health. 2015;48(6):301–9.
Linneberg A, Dam Petersen K, Hahn-Pedersen J, Hammerby E, Serup-Hansen N, Boxall N. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016;14:12.
Sinha B, Vibha, Singla R, Chowdhury R. Allergic rhinitis: a neglected disease—a community based assessment among adults in Delhi. J Postgrad Med. 2015;61(3):169–75.
Bousquet J, Anto JM, Wickman M, Keil T, Valenta R, Haahtela T, et al. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis. Allergy. 2015;70(9):1062–78.
Liu AH, Babineau DC, Krouse RZ, Zoratti EM, Pongracic JA, O’Connor GT, et al. Pathways through which asthma risk factors contribute to asthma severity in inner-city children. J Allergy Clin Immunol. 2016;138(4):1042–50.
• Aguilar D, Pinart M, Koppelman GH, Saeys Y, Nawijn MC, Postma DS, et al. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PLoS One. 2017;12(6):e0179125. This in silico study highlights the molecular mechanisms overlap among AR and asthma.
BioCarta_Pathways [Internet]. [cited2017Nov 2]. Available from:https://cgap.nci.nih.gov/Pathways/BioCarta_Pathways.
Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol. 2009;158(3):260–71.
Kurukulaaratchy RJ, Zhang H, Patil V, Raza A, Karmaus W, Ewart S, et al. Identifying the heterogeneity of young adult rhinitis through cluster analysis in the Isle of Wight birth cohort. J Allergy Clin Immunol. 2015;135(1):143–50.
Braunstahl G-J, Fokkens WJ, Overbeek SE, KleinJan A, Hoogsteden HC, Prins J-B. Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin Exp Allergy. 2003;33(5):579–87.
Burgess JA, Walters EH, Byrnes GB, Matheson MC, Jenkins MA, Wharton CL, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120(4):863–9.
Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarvà M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res. 2005;6(1):153.
Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855–9.
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8.
Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17(27):vi. xi–xiv, 1-322
Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6.
Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, et al. EAACI guidelines on allergen immunotherapy: prevention of allergy. Pediatr Allergy Immunol. 2017;28:728–45.
Platts-Mills TAE, de Weck AL. Dust mite allergens and asthma—a worldwide problem. J Allergy Clin Immunol. 1989;83(2 Pt 1):416–27.
Sporik R, Holgate ST, Platts-Mills TAE, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. N Engl J Med. 1990;323(8):502–7.
Meng Q, Liu X, Li P, He L, Xie J, Gao X, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. Int Forum Allergy Rhinol. 2016;6(8):862–70.
Ulrik CS, Backer V. Markers of impaired growth of pulmonary function in children and adolescents. Am J Respir Crit Care Med. 1999;160(1):40–4.
Huang F-L, Liao E-C, Yu, S-J. House dust mite allergy: its innate immune response and immunotherapy. Immunobiology. 2018;223(3):300–302. https://doi.org/10.1016/j.imbio.2017.10.035.
Venn A, Lewis S, Cooper M, Hill J, Britton J. Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence. BMJ. 1998;316(7149):1945–6.
Geier DA, Kern JK, Geier MR. Demographic and neonatal risk factors for childhood asthma in the USA. J Matern Fetal Neonatal Med. 2017:1–5.
O’Connor GT, Lynch SV., Bloomberg GR, Kattan M, Wood RA, Gergen PJ, et al. Early-life home environment and risk of asthma among inner-city children. Allergy Clin Immunol. 2017. https://doi.org/10.1016/j.jaci.2017.06.040.
Ferrini M, Carvalho S, Cho YH, Postma B, Miranda Marques L, Pinkerton K, et al. Prenatal tobacco smoke exposure predisposes offspring mice to exacerbated allergic airway inflammation associated with altered innate effector function. Part Fibre Toxicol. 2017;14(1):30.
Makadia LD, Roper PJ, Andrews JO, Tingen MS. Tobacco use and smoke exposure in children: new trends, harm, and strategies to improve health outcomes. Curr Allergy Asthma Rep. 2017;17(8):55.
Tanaka K, Miyake Y, Furukawa S, Arakawa M. Secondhand smoke exposure and risk of wheeze in early childhood: a prospective pregnancy birth cohort study. Tob Induc Dis. 2017;15(1):30.
Polosa R, Knoke JD, Russo C, Piccillo G, Caponnetto P, Sarvà M, et al. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. J Allergy Clin Immunol. 2008;121(6):1428–34.
Diaz-Sanchez D, Rumold R, Gong H. Challenge with environmental tobacco smoke exacerbates allergic airway disease in human beings. J Allergy Clin Immunol. 2006;118(2):441–6.
Polosa R, Russo C, Caponnetto P, Bertino G, Sarvà M, Antic T, et al. Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. Respir Res. 2011;12(1):16.
Platts-Mills TAE. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164(supplement_1):S1–5.
Platts-Mills TAE, Woodfolk JA. Allergens and their role in the allergic immune response. Immunol Rev. 2011;242(1):51–68.
Makinen T, Lehtimäki L, Kinnunen H, Nieminen R, Kankaanranta HME. Bronchial diffusing capacity of nitric oxide is increased in patients with allergic rhinitis. Int Arch Allergy Immunol. 2009;148(2):154–60.
Ciprandi G, Tosca MA, Capasso M. Exhaled nitric oxide in children with allergic rhinitis and/or asthma: a relationship with bronchial hyperreactivity. J Asthma. 2010;47(10):1142–7.
Panganiban RP, Wang Y, Howrylak J, Chinchilli VM, Craig TJ, August A, et al. Circulating microRNAs as biomarkers in patients with allergic rhinitis and assthma. J Allergy Clin Immunol. 2016;137(5):1423–32.
Hu D, Zhang Z, Ke X, Kang H, Hong S. A functional variant of miRNA-149 confers risk for allergic rhinitis and comorbid asthma in Chinese children. Int J Immunogenet. 2017;44(2):62–70.
Luo X, Hong H, Tang J, Wu X, Lin Z, Ma R, et al. Increased expression of miR-146a in children with allergic rhinitis after allergen-specific immunotherapy. Allergy Asthma Immunol Res. 2016;8(2):132–40.
Lu L-F, Boldin MP, Chaudhry A, Lin L-L, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142(6):914–29.
Wallace D, Dykewicz M, Bernstein D, Blessingmoore J, Cox L, Khan D, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2):S1–84.
Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.
Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6(10):761–71.
Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218–30.
Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American academy of allergy, asthma & immunology/European academy of allergy and clinical immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–1296.e3.
Şahin E, Bafaqeeh SA, Güven SG, Çetinkaya EA, Muluk NB, Coşkun ZO, et al. Mechanism of action of allergen immunotherapy. Am J Rhinol Allergy. 2016;30(5):1–3.
Polosa R. Can immunotherapy prevent progression to asthma in allergic individuals? J Allergy Clin Immunol. 2002;110(4):672–3.
Baena-Cagnani CE, Larenas-Linnemann D, Teijeiro A, Canonica GW, Passalacqua G. Will sublingual immunotherapy offer benefit for asthma? Curr Allergy Asthma Rep. 2013;13(6):571–9.
Purello-D’Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001;31(8):1295–302.
Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99(4):450–3.
Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001;31(9):1392–7.
Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco ADR, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101(2):206–11.
Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of sew sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol. 2007;17(2):85–91.
Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7.
Polosa R, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, Vancheri C, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy. 2004;59(11):1224–8.
Milani M, Pecora S, Burastero S, Group on behalf of EIS. Observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Curr Med Res Opin. 2008;24(9):2719–24.
• Karakoc-Aydiner E, Eifan A, Baris S, Gunay E, Akturk H, Akkoc T, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite–allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol. 2015;25(255):334–42. This Randomized Controlled Trial shows the efficacy and the prevention effect of SIT in Dust Mite allergic children with AR or mild asthma.
Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538. https://doi.org/10.1016/j.jaci.2017.06.014.
British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/.
Nurmatov U, Dhami S, Arasi S, Roberts G, Pfaar O, Muraro A, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clin Transl Allergy. 2017;7:24.
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017;72(5):691–704.
• Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28(1):18–29. This systematic review provides evidences of a reduced short-term risk of developing asthma in allergic rhinitis subjects treated with SIT.
Ridolo E, Incorvaia C, Gritti BL, Passalacqua G. The current overuse and misuse of meta-analyses on sublingual immunotherapy: the case of grass pollen allergy. Curr Opin Allergy Clin Immunol. 2017;17(1):12–6.
Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;4:CD001186.
Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609.
Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–97.
Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in Infants with episodic wheezing. N Engl J Med. 2006;354(19):1998–2005.
Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet (Lond Engl). 2006;368(9537):754–62.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dr. Morjaria reports non-financial support from Boehringer Ingelheim, during the conduct of the study; personal fees and other from Boehringer Ingelehim; Chiesi; AstraZeneca; Novartis; Teva UK Ltd; Pfizer; and GlaxoSmithKline, outside the submitted work. The other authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Rhinitis
Rights and permissions
About this article
Cite this article
Morjaria, J.B., Caruso, M., Emma, R. et al. Treatment of Allergic Rhinitis as a Strategy for Preventing Asthma. Curr Allergy Asthma Rep 18, 23 (2018). https://doi.org/10.1007/s11882-018-0781-y
Published:
DOI: https://doi.org/10.1007/s11882-018-0781-y